Maria Pernemalm

Maria Pernemalm

Auto-generated profile, based on publicly available information

Maria Pernemalm

Department of Oncology-Pathology, Karolinska Institute, 171 77 Stockholm, Sweden; Science for Life Laboratory, Tomtebodavägen 23, 171 65 Solna, Sweden

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2014 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
SWSteven L. Wood
Steven L. Wood
MPMaria Pernemalm
Maria Pernemalm
PCPhil Crosbie
Phil Crosbie
AWAnthony Whetton
Anthony Whetton

22 July 2021 in Journal of Extracellular Vesicles
Verified
Journal Article
Open access
PDF file
RVRosanne E. Veerman
Rosanne E. Veerman
LTLoes Teeuwen
Loes Teeuwen
PCPaulo Czarnewski
Paulo Czarnewski
GAGözde Güclüler Akpinar
Gözde Güclüler Akpinar
ASAnnSofi Sandberg
AnnSofi Sandberg
MEMaria Eldh
Maria Eldh
Extracellular vesicles (EVs) are increasingly tested as therapeutic vehicles and biomarkers, but still EV subtypes are not fully characterised. To isolate EVs with few co‐isolated entities, a combination of methods is needed. However, this is time‐consuming and requires large sample volumes, often not feasible in most clinical studies or in studies where small sample volumes are available. Therefore, we compared EVs rendered by five commonly used methods based on different principles from conditioned cell medium and 250 μl or 3 ml plasma, that is, precipitation (ExoQuick ULTRA), membrane affinity (exoEasy Maxi Kit), size‐exclusion chromatography (qEVoriginal), iodixanol gradient (OptiPrep), and phosphatidylserine affinity (MagCapture). EVs were characterised by electron microscopy, Nanoparticle Tracking Analysis, Bioanalyzer, flow cytometry, and LC‐MS/MS. The different methods yielded samples of different morphology, particle size, and proteomic profile. For the conditioned medium, Izon 35 isolated the highest number of EV proteins followed by exoEasy, which also isolated fewer non‐EV proteins. For the plasma samples, exoEasy isolated a high number of EV proteins and few non‐EV proteins, while Izon 70 isolated the most EV proteins. We conclude that no method is perfect for all studies, rather, different methods are suited depending on sample type and interest in EV subtype, in addition to sample volume and budget.

21 October 2021 in Journal of Proteome Research
Verified
Journal Article
Closed access
EDEric W. Deutsch
Eric W. Deutsch
GOGilbert S. Omenn
Gilbert S. Omenn
ZSZhi Sun
Zhi Sun
MMMichal Maes
Michal Maes
MPMaria Pernemalm
Maria Pernemalm
JSJochen Schwenk
Jochen Schwenk

27 May 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
Kariem EzzatKariem Ezzat
Kariem Ezzat
MPMaria Pernemalm
Maria Pernemalm
SPSandra Pålsson
Sandra Pålsson
TRThomas C. Roberts
Thomas C. Roberts
PJPeter Järver
Peter Järver
SASamir EL Andaloussi
Samir EL Andaloussi
Artificial nanoparticles accumulate a protein corona layer in biological fluids, which significantly influences their bioactivity. As nanosized obligate intracellular parasites, viruses share many biophysical properties with artificial nanoparticles in extracellular environments and here we show that respiratory syncytial virus (RSV) and herpes simplex virus type 1 (HSV-1) accumulate a rich and distinctive protein corona in different biological fluids. Moreover, we show that corona pre-coating differentially affects viral infectivity and immune cell activation. In addition, we demonstrate that viruses bind amyloidogenic peptides in their corona and catalyze amyloid formation via surface-assisted heterogeneous nucleation. Importantly, we show that HSV-1 catalyzes the aggregation of the amyloid β-peptide (Aβ42), a major constituent of amyloid plaques in Alzheimer’s disease, in vitro and in animal models. Our results highlight the viral protein corona as an acquired structural layer that is critical for viral–host interactions and illustrate a mechanistic convergence between viral and amyloid pathologies.

1 April 2015 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
SWSteven L. Wood
Steven L. Wood
MPMaria Pernemalm
Maria Pernemalm
PCPhil Crosbie
Phil Crosbie
AWAnthony Whetton
Anthony Whetton

11 September 2012 in BMC Bioinformatics
Verified
Journal Article
Open access
PDF file
AAAndrey Alexeyenko
Andrey Alexeyenko
WLWoojoo Lee
Woojoo Lee
MPMaria Pernemalm
Maria Pernemalm
JGJustin Guegan
Justin Guegan
PDPhilippe Dessen
Philippe Dessen
YPYudi Pawitan
Yudi Pawitan
Background: Gene-set enrichment analyses (GEA or GSEA) are commonly used for biological characterization of an experimental gene-set. This is done by finding known functional categories, such as pathways or Gene Ontology terms, that are over-represented in the experimental set; the assessment is based on an overlap statistic. Rich biological information in terms of gene interaction network is now widely available, but this topological information is not used by GEA, so there is a need for methods that exploit this type of information in high-throughput data analysis. Results: We developed a method of network enrichment analysis (NEA) that extends the overlap statistic in GEA to network links between genes in the experimental set and those in the functional categories. For the crucial step in statistical inference, we developed a fast network randomization algorithm in order to obtain the distribution of any network statistic under the null hypothesis of no association between an experimental gene-set and a functional category. We illustrate the NEA method using gene and protein expression data from a lung cancer study. Conclusions: The results indicate that the NEA method is more powerful than the traditional GEA, primarily because the relationships between gene sets were more strongly captured by network connectivity rather than by simple overlaps.